Drugs / A197
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05238597 | Jan 2022 → Jan 2023 | dry eye syndrome | Aramis Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238597 ↗ |